Buzz to business or bust – Google Life Sciences’ Verily

The Baseline Study - Integration of personal and external information/population of human health and transition to disease e.g. understanding the mutations over time and before onset of disease through exams

Collection and analysis of viruses / malware to credit history or spending trends may have been the normal for some (long) time but health data collection in fitness bands and rapid digital health records might be unique identifiers that cannot be easily changed/replaced in comparison.  Yet the corresponding data confidentiality/integrity protection is finally being noticed.  Of course, the centerpiece bringing it to the forefront is availability and affordability of digital/wearable devices, for example, but the ramification on personal life and health is invaluable.  The launch of the
spinoff Verily, preceded / advanced the stacking of leading researchers and biomedicine experts including Harvard grad Medical Officer, Technology officer from Univ of Washington and other Google principals in business developments.  Moreover, it will also land itself in competing with tech companies including Apple as well as a furry of bio-tech startups.  Aside from running experimental genetics and clinical studies, the company makes miniaturized medical devices with intelligence/software and licenses them to medical companies and pharmaceutical…
Key pursuits reported by recode.net including:

• Diabetes partnerships (Novartis, Dexcom, Sanofi)
• Multiple sclerosis partnerships (Biogen Inc. for wearable sensors)
• Nanodiagnostics (by taking a tiny pill and monitoring with wearable devices)
• Liftware (Parkinson’s disease study)
• Heart Disease (diabetes with American Health Association’s $50M funding)
• Metal Health
• And, probably most known/hyped for Robots (Johnson & Johnson robot joint venture)

And of course, Baseline – underplayed genomic, molecular and cellular science but really big data of volunteers prepped for studied.  A record 10,000 patients records are to be collected over the next 5 years which has sparked some so-so debate about ethical and privacy, including resonance of the patients or profiling such as socioeconomic, psychosocial, geospatial and genetic data.  Of course, some of the turmoil is occurring internally as the scientist and business worlds collide. But patient health and ethnics will align; or at least preventive health will prevail, right

The upshot is basically preventative care by merging technology and life sciences by identifying trends / synergy of health and reactive approach to disease management.  So, the innovation and ecosystem of disease and treatment will offer Patient Management set of Services in a Healthcare centric platform.